Analysis of HLA-E expression in human tumors.

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2011) 3.66

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17

Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15

Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer (2013) 1.15

Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy (2011) 1.11

Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06

The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol (2010) 1.05

CD56(dim)CD57(+)NKG2C(+) NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia (2015) 0.96

Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology (2013) 0.92

A GATA factor mediates cell type-restricted induction of HLA-E gene transcription by gamma interferon. Mol Cell Biol (2004) 0.90

Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One (2009) 0.89

Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One (2011) 0.86

Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer (2014) 0.85

HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med (2012) 0.85

LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics (2006) 0.84

Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. Curr Oncol (2012) 0.82

HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med (2013) 0.82

Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems. Am J Cancer Res (2016) 0.81

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat (2015) 0.81

Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer. Int J Breast Cancer (2013) 0.81

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother (2015) 0.79

Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. Br J Cancer (2014) 0.79

Irradiation-induced up-regulation of HLA-E on macrovascular endothelial cells confers protection against killing by activated natural killer cells. PLoS One (2010) 0.78

Non-classical MHC-E (Mamu-E) expression in the rhesus monkey placenta. Placenta (2007) 0.76

IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-γ release by autologous NK cells. J Immunol Res (2014) 0.76

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology (2015) 0.76

HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02. PLoS One (2015) 0.75

Antigen Loss Variants: Catching Hold of Escaping Foes. Front Immunol (2017) 0.75

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 7.12

Viral strategies of immune evasion. Science (1998) 4.48

HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A (1998) 3.35

Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science (2000) 3.20

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today (1997) 2.89

The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol (1997) 2.36

The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J (1983) 2.28

HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol (1998) 2.09

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer (2001) 2.07

Natural history of HLA expression during tumour development. Immunol Today (1993) 2.04

Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature (1992) 1.79

TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol (1998) 1.70

HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol (1998) 1.60

Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol (1990) 1.48

MHC antigens and tumor escape from immune surveillance. Adv Cancer Res (2001) 1.45

HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol (1995) 1.39

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A (1994) 1.29

Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer (1999) 1.00

Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol (1999) 0.96

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens (1998) 0.95

Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens (2000) 0.93

Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens (1996) 0.91

Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol (2000) 0.90

Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol (2002) 0.84

Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol (2000) 0.83

High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol (2000) 0.83

Differences among various class I molecules in competition for beta2m in vivo. Immunogenetics (1996) 0.82

Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells. Clin Sci (Lond) (2000) 0.81

Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens (2001) 0.81

In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. Int J Cancer (1998) 0.80

High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int J Cancer (2000) 0.78

Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens (2000) 0.78

Genetic divergence of the rhesus macaque major histocompatibility complex. Genome Res (2004) 2.32

The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev (2002) 2.21

Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol (2006) 2.08

Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01

Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol (2007) 1.92

MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol (2003) 1.87

Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One (2010) 1.62

Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol (2006) 1.62

Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61

Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol (2003) 1.60

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58

HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol (2010) 1.39

HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem (2002) 1.38

NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood (2010) 1.38

[Cystinosis: diagnosis through the measurement of the leukocyte cystine content by HPLC]. Med Clin (Barc) (2004) 1.37

Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis (2006) 1.31

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother (2004) 1.31

Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. Genomics (2006) 1.28

Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol (2005) 1.27

MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol (2007) 1.24

Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol (2007) 1.22

Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J Infect Dis (2011) 1.20

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 1.18

High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles. Immunogenetics (2007) 1.17

Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Immunogenetics (2003) 1.16

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother (2012) 1.15

Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother (2004) 1.15

Nomenclature for Factors of the HLA System, 2004. Hum Immunol (2005) 1.14

High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol (2007) 1.08

A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation. BMC Cancer (2006) 1.08

HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors. J Immunol (2013) 1.05

Soluble HLA-G isoforms: technical deficiencies lead to misinterpretations. Mol Hum Reprod (2005) 1.05

Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet (2013) 1.05

Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol (2008) 1.04

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis (2013) 1.04

Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica (2004) 1.04

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (2008) 1.03

Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics (2010) 1.03

Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother (2002) 1.03

HLA-F is a surface marker on activated lymphocytes. Eur J Immunol (2010) 1.03

Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Hum Immunol (2003) 1.00

Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer (2008) 0.99

Recombinant structures expand and contract inter and intragenic diversification at the KIR locus. BMC Genomics (2013) 0.98

HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol (2010) 0.98

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer (2003) 0.97

HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol (2003) 0.97

MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis (2012) 0.95

Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood (2007) 0.95

IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res (2008) 0.94

Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol (2007) 0.93

Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Hum Immunol (2012) 0.93

HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol (2013) 0.92

A soluble isoform of the rhesus monkey nonclassical MHC class I molecule Mamu-AG is expressed in the placenta and the testis. J Immunol (2002) 0.91

Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat (2006) 0.91

Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer (2005) 0.91

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother (2008) 0.91

Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother (2005) 0.91

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer (2003) 0.90

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol (2012) 0.90

Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother (2002) 0.90

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother (2009) 0.90

HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines haplotype structure and variation spanning the nonclassical class I genes. Immunogenetics (2006) 0.89

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother (2006) 0.89

Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J Gastroenterol (2005) 0.88

VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol (2012) 0.88

Nomenclature for factors of the HLA system, 2002. Hum Immunol (2002) 0.88

The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer (2008) 0.88

Study of six X-linked tetranucleotide microsatellites: population data from five Spanish regions. Int J Legal Med (2005) 0.88

Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotype. Mutagenesis (2012) 0.87

Relevance of IL-1 and TNF gene polymorphisms on interleukin-1beta and tumor necrosis factor-alpha gastric mucosal production. Hum Immunol (2009) 0.87

HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One (2013) 0.87

High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol (2003) 0.87

T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res (2014) 0.87

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer (2013) 0.86

Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy. Toxins (Basel) (2011) 0.86

Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l. Cancer Lett (2002) 0.86

Analysis of HLA-ABC locus-specific transcription in normal tissues. Immunogenetics (2010) 0.86